Please assess the completion status of the following clinical trial:

Trial Title: Drug Study in Pediatric Subjects With Migraines (MK0462-083 AM1)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Panel A and B: Male and female subjects (non-smokers) ages 6 to 17 with a history of migraines~* Panel C: Male subjects (non-smokers) ages 12 to 17 with a history of migraines~* Subject has a history of migraine headaches, and is not experiencing a migraine on the day of study drug administration~Exclusion Criteria:~* Subject has no history of migraine headaches~* Taking medications that are monoamine oxidase inhibitors (MAOI) and selective serotonin reuptake inhibitors (SSRI)~* Subject has a condition which, in the opinion of the investigator, may interfere with optimal participation in the study

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Panel A Rizatriptan (Type: EXPERIMENTAL): Subjects allocated to Panel A and randomized to receive a single dose of rizatriptan 5 mg orally disintegrating tablet (ODT) on Day 1.~Subjects weighing 20-39 kg were allocated to Panel A.
- Panel A Placebo (Type: PLACEBO_COMPARATOR): Subjects allocated to Panel A and randomized to receive a single dose of rizatriptan 5 mg orally disintegrating tablet (ODT) placebo on Day 1.~Subjects weighing 20-39 kg were allocated to Panel A.
- Panel B Rizatriptan (Type: EXPERIMENTAL): Subjects allocated to Panel B and randomized to receive a single dose of rizatriptan 10 mg orally disintegrating tablet (ODT) on Day 1.~Subjects weighing 40 kg and above were allocated to Panel B.
- Panel B Placebo (Type: PLACEBO_COMPARATOR): Subjects allocated to Panel B and randomized to receive a single dose of rizatriptan 10 mg orally disintegrating tablet (ODT) placebo on Day 1.~Subjects weighing 40 kg and above were allocated to Panel B.
- Panel C Rizatriptan (Type: EXPERIMENTAL): Subjects allocated to Panel C and randomized to receive a single dose of rizatriptan ODT on Day 1. Subjects in Panel C weighing 20-39 kg received a 5 mg dose and subjects weighing 40 kg and above received a 10 mg dose.~Panel C was added to the study by amendment to increase the number of male subjects in the 12-17 year old age group.
- Panel C Placebo (Type: PLACEBO_COMPARATOR): Subjects allocated to Panel C and randomized to receive a single dose of rizatriptan ODT placebo on Day 1. Subjects in Panel C weighing 20-39 kg received a 5 mg placebo dose and subjects weighing 40 kg and above received a 10 mg placebo dose.~Panel C was added to the study by amendment to increase the number of male subjects in the 12-17 year old age group.

Based on this trial design, predict the completion outcome and termination type (if applicable).